A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE
Virology Bookmark and Share

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Experimental Therapeutics
The Department of Experimental Therapeutics was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology Faculty

Virology

Virology

City of Hope’s Department of Virology strives to better understand the origin and development of herpes simplex virus and other herpes viruses, the biology of cytomegalovirus (a prime concern for HIV-infected and other immunocompromised patients such as transplant recipients), vaccine development and experimental therapies using gene transfer vectors such as adeno-associated virus (AAV) and lentivirus. Viral vectors have shown great promise in treating both cancers and HIV.

John A. Zaia, M.D., chair of the department, plays an integral role in the Hematopoietic Cell Transplantation Program’s efforts to understand the biology of cytomegalovirus (CMV)-related pneumonitis, which was a major limitation to the success of bone marrow transplantation, and later went on to develop the gene therapy program at City of Hope, focused on treatment of HIV with genetically modified stem cells and T cells.

The Department of Virology comprises more than 50 personnel, including professors, associate professors, support scientists, postdoctoral fellows, research associates, laboratory aides and administrative support.
 
Laboratory Research

John Zaia, M.D. – Antiviral Research
Zaia, department chair, joined City of Hope from Harvard in 1980. He directs two clinical research labs, the Cytomegalovirus (CMV) Lab and the HIV Lab, with interests in antiviral development in the area of herpes viruses and HIV. The CMV laboratory studies the immunobiology of CMV infection after hematopoietic cell transplantation (HCT) with emphasis on immune factors necessary for protection. The HIV laboratory focuses on developing new treatments for HIV/AIDS using optimal genetic vectors for anti-HIV gene transfer and novel drug therapy.

Edouard Cantin, Ph.D. – Neurovirology and Neuroimmunology
Cantin is director of the Laboratory of Neurovirology and Neuroimmunology. He investigates the role of the host immune response in the pathogenesis herpes simplex virus (HSV) infections in vivo, with particular emphasis on CNS infections and the regulation of latency. His laboratory is also investigating the mechanisms by which intravenous immunoglobulins (IVIG) act as a potent immunomodulatory drug to suppress virus induced hyper-inflammatory responses that in the CNS culminate in fatal encephalitis following infection with HSV or West Nile virus, or fatal pneumonia following infection with highly pathogenic influenza virus strains, such as pandemic H1N1. A long-term interest is to understand the genetic basis of innate resistance to HSV, as this may suggest rational approaches to controlling recurrent infections, and the development of serious diseases such as encephalitis.
 
Saswati Chatterjee, Ph.D. – Gene Therapy
Chatterjee directs the Adeno-Associated Virus (AAV) Laboratory and is interested in the biology of AAV vectors for therapeutic gene transfer. Her specific areas of interest include stem cell-based genetic therapies of acquired and inherited diseases, including HIV infection, cancer, cardiovascular and genetic diseases; virus discovery research in human stem cells and the study of genetic elements necessary for optimal gene-based therapies. She evaluates gene therapy approaches in both in vitro and in vivo pre-clinical models, with targeted progression toward clinical human gene therapy trials.

Jiing-Kuan Yee, Ph.D.Modeling human diseases with stem cells
Dr. Yee is interested in using cell reprogramming and gene editing to establish ex vivo human genetic disease models to explore the underlying disease mechanisms and develop therapeutic strategies for treatment.  He has established fibroblast-derived induced pluripotent stem cells (iPSCs) from spinal muscular atrophy and Wiskott-Aldrich syndrome patients.  He is studying the phenotypes of cells differentiated from these iPSC lines to understand the pathogenesis of the disease.  He is also using gene editing technology to modify the genome of the iPSCs to explore the possibility of treating these diseases with cell replacement therapy.
 
Experimental Therapeutics
The Department of Experimental Therapeutics was formed to address priorities in vaccine research that will potentially impact patient outcomes at City of Hope and other cancer centers worldwide.

Virology Faculty

Virology Faculty

Overview
Beckman Research Institute of City of Hope is responsible for fundamentally expanding the world’s understanding of how biology affects diseases such as cancer, HIV/AIDS and diabetes.
 
 
Research Departments/Divisions

City of Hope is a leader in translational research - integrating basic science, clinical research and patient care.
 

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Our Scientists

Our research laboratories are led by the best and brightest minds in scientific research.
 

City of Hope’s Irell & Manella Graduate School of Biological Sciences equips students with the skills and strategies to transform the future of modern medicine.
Develop new therapies, diagnostics and preventions in the fight against cancer and other life-threatening diseases.
 


NEWS & UPDATES
  • Think twice before tossing out those hormone replacement pills. Although a new Lancet study suggests that hormone replacement therapy could increase a woman’s risk of ovarian cancer, a City of Hope expert urges women to keep this news in perspective. Hormone replacement therapy is prescribed to help allev...
  • Don’t know what to take, or send, that friend of yours in the hospital? Try a paper plate — filled not with cookies or sweets, but an image of yourself. Ilana Massi, currently undergoing treatment at City of Hope for acute myeloid leukemia, can vouch for the power of such a gift. She’s surrounded herself [̷...
  • With precision medicine now a national priority, City of Hope has joined a novel research partnership designed to further understanding of cancer at the molecular level, ultimately leading to more targeted cancer treatments. The Oncology Research Information Exchange Network, or ORIEN, is the world’s larg...
  • The spinal cord is an integral part of the human body, connecting the brain to everything else. So when a tumor grows on the spine, any messages that the brain tries to send to the rest of the body are interrupted, making everyday tasks — such as walking — more difficult. This year an estimated 22,850 […]
  • Each year, thousands of patients with hematologic malignancies undergo allogeneic stem cell transplantation (that is, they receive a donor’s stem cells), offering them a chance at cure. Graft-versus-host disease is a potentially deadly complication of this therapy and occurs in approximately 25 to 60 perc...
  • Bertram Yuh, M.D., assistant clinical professor in the Division of Urology and Urologic Oncology at City of Hope, offers his perspective on the benefits of surgery for aggressive prostate cancer. For men walking out of the doctor’s office after a diagnosis of cancer, the reality can hit like a ton of bricks. Th...
  • Although many Hispanic women face a high risk of mutations in the BRCA1 and BRCA2 genes – increasing their risk of breast and ovarian cancer – screenings for these mutations can be prohibitively expensive in Mexico and other Latin American countries. As a result, too many women don’t get the information t...
  • Providing lung cancer treatments to patients when their cancer is at its earliest and most treatable stages will now be a more attainable goal: Medicare has agreed to cover lung cancer screening for those beneficiaries who meet the requirements. The only proven way to detect lung cancer early enough to save liv...
  • At City of Hope, innovative scientific research, important clinical studies and vital construction projects are all powered by philanthropy. Generous supporters fuel a powerful and diverse range of progress in science and medicine, enabling researchers and clinicians to improve cancer treatments and create cure...
  • Trevor Hoffman was only 21 when he was diagnosed with a rare form of cancer, but not even cancer could keep him off his motorcycles. (He has one for racing, and a couple just for fun.) Now a cancer survivor, Hoffman, who lives in La Verne, California, wrapped up his treatment Jan. 19 – just one day […]
  • Valentine’s Day is synonymous with dinner reservations, red roses, heart-shaped boxes of chocolates and — more often than not — unrealistically high expectations. Managing those expectations is great advice for all couples on Feb. 14 — and is especially important for couples confronting a cancer diagnosis. Focu...
  • With measles, what starts at a theme park in California definitely doesn’t stay at a theme park in California. Since the beginning of the current measles outbreak – traced to an initial exposure at Disneyland or Disney California Adventure during December – more than 100 people have been diagnosed with a diseas...
  • Even the most loving and secure relationship can be rattled by a life-threatening illness. When a woman is diagnosed with breast cancer, research shows one of the most important factors in helping her cope is having a supportive partner. But that partner can struggle with knowing what to say or how to best supp...
  • It’s been more than a century since Nobel Laureate Paul Ehrlich popularized the idea of a “magic bullet” targeting disease. Cancer researchers ever since have remained in hot pursuit of targeted therapies that home in on cancer cells while leaving normal cells unaffected. Linda Malkas, Ph.D., associate chair of...
  • Cancer patients face a daunting journey marked by challenges and uncertainties. For those undergoing bone marrow, or stem cell, transplantation, one complication poses a particular threat — chronic graft-versus-host disease (GVHD). Now, one researcher may have found a better way to control that threat. GVHD res...